Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults -Spero and Meiji Seika Pharma Co., LTD. announce an exclusive license partnership for SPR994 -FDA grants SPR994 Qualified Infectious Disease Product (QIDP) status for complicated urinary tract...

Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...

Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team Cristina Larkin promoted to Chief Operating Officer Timothy Keutzer Promoted to Senior Vice President, Development CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a...